FDA granted IND clearance for RV-01 study, which was developed by a joint venture involving Radiopharm Theranostics and based at The University of Texas MD Anderson Cancer Center.
3 reports, 2 independent
Updated Aug 26
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted IND clearance for RV-01 study, which was developed by a joint venture involving Radiopharm Theranostics and based at The University of Texas MD Anderson Cancer Center.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.IND clearance granted by FDA for RV-01 study.1 source
Sartor joins Radiopharm's SAB as company pursues FDA approval for new therapies.1 source
Keep exploring
The entities involved
- FDA
-
The University of Texas MD Anderson Cancer Center
hospital in Texas, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireRadiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01) Lu177-B7H3 monoclonal antibody is first in class targeted
- GlobeNewswireDr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biophar